These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 9652687)

  • 1. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.
    Carr A; Samaras K; Chisholm DJ; Cooper DA
    Lancet; 1998 Jun; 351(9119):1881-3. PubMed ID: 9652687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV protease inhibitor-related lipodystrophy syndrome.
    Carr A
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S135-42. PubMed ID: 10860898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
    Carr A; Samaras K; Burton S; Law M; Freund J; Chisholm DJ; Cooper DA
    AIDS; 1998 May; 12(7):F51-8. PubMed ID: 9619798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review.
    Graham NM
    J Acquir Immune Defic Syndr; 2000 Oct; 25 Suppl 1():S4-11. PubMed ID: 11126425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.
    Carr A; Samaras K; Thorisdottir A; Kaufmann GR; Chisholm DJ; Cooper DA
    Lancet; 1999 Jun; 353(9170):2093-9. PubMed ID: 10382692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Blood lipid abnormalities during treatment with protease inhibitors].
    Vergès B; Petit JM
    Presse Med; 2001 May; 30(18):911-4. PubMed ID: 11413853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Dysmetabolic syndrome related to HIV-1 protease inhibitors. Review of the literature and personal data].
    Urso R; Croce GF; Tubili C; De Marco M; La Scala P; Luglio D; Narciso P
    Recenti Prog Med; 2000 Feb; 91(2):78-85. PubMed ID: 10748653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human obesity and thinness, hyperlipidemia, hyperglycemia, and insulin resistance associated with HIV1 protease inhibitors. Prevention by alternating several antiproteases in short sequences.
    Mathé G
    Biomed Pharmacother; 1999 Dec; 53(10):449-51. PubMed ID: 10665336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lipodystrophy and 'buffalo hump' during treatment with HIV protease inhibitors].
    Dieleman JP; Hillebrand-Haverkort ME; van der Ende ME; Sturkenboom MC; Lange JM; Stricker BH
    Ned Tijdschr Geneeskd; 1998 Dec; 142(52):2856-60. PubMed ID: 10065260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visceral fat as target of highly active antiretroviral therapy-associated metabolic syndrome.
    Barbaro G
    Curr Pharm Des; 2007; 13(21):2208-13. PubMed ID: 17627554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Syndrome of lipodystrophy, hyperlipidemia, insulin resistance, and diabetes in treated patients with human immunodeficiency virus infection.
    Graber AL
    Endocr Pract; 2001; 7(6):430-7. PubMed ID: 11747278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Metabolic complications associated with use of protease inhibitors].
    Mosnier-Pudar H
    Ann Med Interne (Paris); 2000 Jun; 151(4):278-82. PubMed ID: 10922955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse drug reactions to protease inhibitors.
    Manchanda T; Schiedel D; Fischer D; Dekaban GA; Rieder MJ
    Can J Clin Pharmacol; 2002; 9(3):137-46. PubMed ID: 12422251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperlipidemia and inhibitors of HIV protease.
    Distler O; Cooper DA; Deckelbaum RJ; Sturley SL
    Curr Opin Clin Nutr Metab Care; 2001 Mar; 4(2):99-103. PubMed ID: 11224652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of HIV protease inhibitor therapy on lipid metabolism.
    Hui DY
    Prog Lipid Res; 2003 Mar; 42(2):81-92. PubMed ID: 12547652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of high grade antiretroviral therapy on body fat distribution and metabolism].
    Schwenk A
    Zentralbl Gynakol; 1999; 121(11):552-3. PubMed ID: 10612226
    [No Abstract]   [Full Text] [Related]  

  • 17. Lack of mutations in LMNA, its promoter region, and the cellular retinoic acid binding protein II (CRABP II) in HIV associated lipodystrophy.
    Behrens GM; Genschel J; Schmidt RE; Schmidt HH
    Eur J Med Res; 2003 May; 8(5):221-5. PubMed ID: 12844477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors.
    Rudich A; Ben-Romano R; Etzion S; Bashan N
    Acta Physiol Scand; 2005 Jan; 183(1):75-88. PubMed ID: 15654921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dyslipidemia in the era of HIV protease inhibitors.
    Stein JH
    Prog Cardiovasc Dis; 2003; 45(4):293-304. PubMed ID: 12638093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance.
    Bastard JP; Caron M; Vidal H; Jan V; Auclair M; Vigouroux C; Luboinski J; Laville M; Maachi M; Girard PM; Rozenbaum W; Levan P; Capeau J
    Lancet; 2002 Mar; 359(9311):1026-31. PubMed ID: 11937183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.